NGM Biopharmaceuticals, Inc. Profile Avatar - Palmy Investing

NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an enginee…

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

NGM Biopharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of NGM's Analysis
CIK: 1426332 CUSIP: 62921N105 ISIN: US62921N1054 LEI: - UEI: -
Secondary Listings
NGM has no secondary listings inside our databases.